CDX2 and colorectal carcinoma: In agreement with the results from the UK cohorts, results from our study, which, to the best of our knowledge, are the largest to investigate joint associations of VitD status and Cdx2 genotype with survival outcomes in CRC patients, do not seem to support advantages of those with the AA/AG genotype with respect to CRC survival in these Caucasian populations.